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A B S T R A C T
Background
Granulocyte colony stimulating factor (G-CSF) is a naturally-occurring cytokine that has been shown to increase neutrophil function
and number. Exogenous administration of recombinant G-CSF (filgrastim, pegfilgrastim or lenograstim) has found extensive use in
the treatment of febrile neutropenia, but its role in the treatment of infection in non-neutropenic hosts is less well defined.
Objectives
We explored the role of G-CSF as an adjunct to antibiotics in the treatment of pneumonia in non-neutropenic adults.
Search methods
For this updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2006,
issue 4); MEDLINE (1950 to January 2007); EMBASE (1988 to January 2007); and online databases of clinical trials (www.controlled-
trials.com, updated 10 November, 2006).
Selection criteria
We considered randomized controlled trials (RCTs) which included hospitalized adult patients with either community-acquired pneu-
monia or hospital-acquired pneumonia.
Data collection and analysis
Two review authors independently extracted data and assessed trial quality. The primary outcome measure was 28-day mortality.
Secondary outcome measures included other markers of mortality as well as markers of adverse events, including organ dysfunction.
An assessment of methodological quality was made for each study.
Main results
Six studies with a total of 2018 people were identified. G-CSF use appeared to be safe with no increase in the incidence of total serious
adverse events (pooled odds ratio (OR) 0.91; 95% confidence interval (CI): 0.73 to 1.14) or organ dysfunction. However, the use of
G-CSF was not associated with improved 28-day mortality (pooled OR 0.81; 95% CI: 0.52 to 1.27).
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Authors’ conclusions
There is no current evidence supporting the routine use of G-CSF in the treatment of pneumonia. Studies in which G-CSF is
administered prophylactically or earlier in therapy may be of interest.
P L A I N L A N G U A G E S U M M A R Y
Granulocyte colony stimulating factor (G-CSF), when given with antibiotics, does not appear to reduce mortality in adults
with pneumonia
Pneumonia, or infection involving the lungs, is responsible for a significant number of deaths worldwide. Pneumonia is especially
life-threatening in older people and people with other illnesses that may affect the immune system (such as diabetes). In addition to
antibiotics, granulocyte colony stimulating factor (G-CSF) has been suggested as a possible option for treatment. G-CSF stimulates the
production of white blood cells that fight infection, and is used for people with cancer after chemotherapy, and in febrile neutropenia
(infection associated with very low levels of white cells). The review of trials found that, when combined with antibiotics, G-CSF
appears to be a safe treatment for people with pneumonia, but it does not appear to reduce mortality. More research is needed to define
the optimal timing of dosing (earlier, or prophylactically before the onset of infection) and possible problems when given to patients
with severe infection.
B A C K G R O U N D
Description of the condition
This review explores the use of granulocyte-colony stimulating fac-
tor (G-CSF) as an adjunct to antibiotics in the treatment of bacte-
rial pneumonia in non-neutropenic adults. Much of the mortality
associated with pneumonia is related to sepsis, thought to repre-
sent a state of uncontrolled inflammation. Immunomodulation of
this response, using physiological doses of corticosteroids (Annane
2002) and recombinant activated protein C (Bernard 2001) have
been associated with improved outcomes. G-CSF, a naturally oc-
curring cytokine, may augment the neutrophil response to bacte-
rial infections.
Description of the intervention
Recombinant G-CSF (filgrastim, lenograstim) has been shown to
increase proliferation and differentiation of neutrophil precursors.
It has found widespread use in reducing the duration of febrile
neutropenia following cytotoxic chemotherapy (Welte 1996), al-
though its effect on mortality is questionable (Berghmans 2002).
Other accepted indications include neutropenia following bone
marrow transplantation, themobilization of peripheral blood pro-
genitor cells in healthy donors and in the treatment of severe con-
genital neutropenia.
How the intervention might work
Its use in non-neutropenic bacterial infection is based on three
possible mechanisms of action: (1) enhanced chemotaxis, super-
oxide production and bacterial killing activity (Hartung 1999);
(2) immunomodulation of the cytokine response in sepsis (Weiss
1999); and (3) a possible increase in intracellular uptake of antibi-
otics (McKenna 1996).
However, a possible concern with its use in sepsis is the role of neu-
trophils in the development of organdysfunction, and inparticular
acute respiratory distress syndrome (ARDS). Increasingneutrophil
number and function may increase the risk of these adverse seque-
lae. A review of 84 cases of probable G-CSF related pulmonary
toxicity, mostly administered following chemotherapy, found that
G-CSFmight increase the toxicity associatedwith cytotoxic agents
and infectious insults in neutropenic patients (Azoulay 2001).
G-CSF has shown promise in the treatment of infection in non-
neutropenic hosts in many animal models (Hebert 1990; Smith
1995) and in at least one case series with a historical control group
(Stephens 2002). It should be distinguished from GM-CSF (sar-
gramostim), which is used occasionally in stem cell mobilization
and to promote engraftment following bone marrow transplanta-
tion.
Why it is important to do this review
Community-acquired pneumonia is the leading cause of death
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from infectious disease and results in approximately 600,000 ad-
missions per year in the United States (Bartlett 1995). Both
community-acquired pneumonia and hospital-acquired pneumo-
nia are associated with a significant mortality (Fagon 1993a;
Niederman 1993). A number of trials of G-CSF in the treatment
of pneumonia have been performed. A review of these trials may
clarify the role of this immunomodulatory therapy and aid design
of future trials.
O B J E C T I V E S
To assess the efficacy and safety of G-CSF as an adjunct to antibi-
otics for the treatment of pneumonia in non-neutropenic adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomized controlled trials were included in this review.
Types of participants
The population studied included hospitalized adult patients (older
than 18 years) with:
1. community-acquired pneumonia;
2. hospital-acquired pneumonia, including ventilator-
associated pneumonia.
“Community-acquired pneumonia” was defined as follows (BTS
2001):
1. clinical features suggestive of lower respiratory tract
infection (such as fever, cough, pleuritic chest pain, examination
suggestive of consolidation);
2. chest X-ray demonstrating new infiltrate suggesting
pneumonia;
3. onset in community setting (outpatient or less than 48
hours following admission to hospital);
4. no alternative diagnosis at admission or during follow up.
There has been controversy regarding the optimal definition of
hospital-acquired pneumonia (Fagon 1993b) and a paucity of
studies of mortality. In general, hospital-acquired pneumonia is
associated with a high mortality (Fagon 1993a). In this review,
we regard “hospital-acquired pneumonia” as a clinical definition
(ATS 2005; Garner 1988):
1. onset of illness more than 72 hours following admission;
2. new infiltrate on chest X-ray;
3. signs of sepsis (leucocytosis, fever, tachypnoea, tachycardia);
4. increasing sputum production;
5. no alternative diagnosis (such as Acute Respiratory Distress
Syndrome (ARDS)) at time of evaluation or follow up.
“Suspected ventilator associated pneumonia”, a sub-set of patients
with hospital-acquired pneumonia, was defined as:
1. hospital-acquired pneumonia (defined above);
2. patients intubated for more than 72 hours.
“Confirmed ventilator associated pneumonia” was defined as 1
and 2 above, supported by quantitativemicrobiological techniques
(Sanchez-Nieto 1998), including:
1. protected specimen brush sampling with quantitative
culture techniques;
2. quantitative cultures of bronchoalveolar lavage;
3. quantitative cultures of endotracheal aspirates.
We had originally intended to only include patients with severe
community-acquired pneumonia, but subsequently found that the
studies we identified were performed prior to the development of
standard definitions of severity (Ewig 1998; Fine 1997;Niederman
1993). We thus incorporated a group with “severe sepsis”, defined
by standard criteria (Bone 1993) which detail definitions of sepsis
(fever, tachycardia, tachypnoea and leucocytosis) and end-organ
perfusion abnormalities (hypotension, oliguria, gas exchange ab-
normalities).
A sensitivity analysis would have been performed excluding studies
in which there was uncertainty if the specific inclusion criteria
were met.
We excluded studies specifically involving neutropenic patients or
patients following chemotherapy.
Types of interventions
We assessed the use of G-CSF as an adjunct to antibiotics. We
included studies involving all doses of G-CSF administered intra-
venously or subcutaneously. Trials that allowed concurrent use of
other therapies, including mechanical ventilation, immunomod-
ulatory agents including steroids, bronchodilators and so on were
included if they allowed equal access to such medications for pa-
tients in both arms of the trial.
Types of outcome measures
Primary outcomes
The primary outcome was 28-day mortality.
Secondary outcomes
1. In-hospital mortality.
2. Rate of mechanical ventilation.
3. Duration of intensive care unit (ICU) admission following
randomization.
4. Duration of hospital admission following randomization.
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5. Adverse events, including the incidence of organ failure
(ARDS, disseminated intravascular coagulation, acute renal
failure, development of shock).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases for the first publi-
cation of this review in mid-2003. Searches were updated in 2004
and 2007.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, 2006, issue 4); MEDLINE
(1950 to January 2007); EMBASE (1988 to January 2007); and
online databases of clinical trials (www.controlled-trials.com, up-
dated 10 November, 2006).
We searched MEDLINE and CENTRAL using the following
search strategy combined with the highly sensitive search strat-
egy suggested in the Cochrane Reviewers Handbook 5.2 (Higgins
2005) for identification of randomized clinical trials (see below).
For the EMBASE search strategy see Appendix 1. We included
studies in all languages. Studies identified as randomized con-
trolled trials in non-neutropenic adults were examined further for
eligibility.
MEDLINE (OVID)
#1 exp pneumonia/
#2 exp respiratory tract infection/
#3 or/1-2
#4 exp Community-Acquired Infections/
#5 3 and 4
#6 exp cross infection/
#7 exp ventilators, mechanical/
#8 or/6-7
#9 3 and 8
#10 (community-acquired pneumonia or CAP).mp.
#11 (hospital acquired pneumonia or HAP).mp.
#12 nosocomial pneumonia.mp.
#13 (ventilator associated pneumonia or VAP).mp.
#14 exp Sepsis/
#15 or/1,5,9-14
#16 exp granulocyte colony stimulating factor/
#17 g-csf.mp.
#18 lenograstim.mp.
#19 exp Filgrastim/
#20 filgrastim.mp.
#21 pegfilgrastim.mp.
#22 or/16-21
#23 15 and 22
Searching other resources
We also contacted corresponding authors, contacted the manu-
facturers and distributors of filgrastim (Amgen) and lenograstim
(Chugai, Japan and Merck, Australia); and reviewed citations in
publications identified by the above strategies.
Data collection and analysis
Data extraction and management
Two review authors independently extracted data. Disagreements
were resolved by discussion.
Data that were extracted included, where possible:
1. description of participants and recruitment;
2. description of pathogens and antimicrobial resistance;
3. description of intervention and co-interventions;
4. description of control therapy;
5. description of antibiotics used;
6. methodological details, including criteria for quality
assessment (below);
7. total number of participants in each arm of the trial;
8. study setting, in particular intensive care unit (ICU) versus
non-ICU;
9. markers of duration of morbidity, including intubation,
time to discharge from ICU and hospital;
10. mortality; in-hospital and 28 day;
11. adverse events, including organ dysfunction;
12. source of funding.
Two review authors assessed study quality based on standard
Cochrane criteria for the assessment of the following components
of study design (Alderson 2004):
1. generation of allocation sequence;
2. allocation concealment;
3. blinding;
4. loss to follow up.
We did not exclude studies of poor methodology from the primary
analysis.
We assessed population, intervention and outcome measures of
each study to see if the pooling of results was feasible. Hetero-
geneity was tested using the chi squared test. However, given the
intrinsic heterogeneity of the study populations, random-effects
analysis was to be employed if pooling was still felt to be appro-
priate. It was intended that where appropriate, we would calculate
relative risk/odds ratios, event rates, time-to-event and risk dif-
ference and corresponding 95% CIs. We analyzed the data using
Review Manager (version 4.2).
Publication bias was to be assessed by the use of a “funnel plot”.
Subgroup analysis and investigation of heterogeneity
4Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Intended a priori subgroup analyses, where possible, were to be
performed for:
1. age category (older than 65 years);
2. patients with specific chronic diseases (diabetes, renal
failure, hazardous alcohol use, chronic obstructive airways
disease) separately;
3. bacterial aetiology;
4. community-acquired pneumonia, hospital-acquired
pneumonia and suspected and confirmed ventilator-associated
pneumonia separately;
5. patients with and without severe sepsis.
Sensitivity analysis
It was intended that a sensitivity analysis would be performed ex-
cluding studies of low methodological quality, unpublished stud-
ies and studies where some ambiguity exists about whether they
met inclusion criteria.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Following a MEDLINE (OVID) search, we identified 93 stud-
ies for screening. Of these, 87 studies were excluded (duplicate
studies, animal studies, studies of neonatal or pediatric patients,
studies of neutropenic patients or patients following chemother-
apy or transplantation, studies that did not assess G-CSF as ther-
apy (mainly basic science articles), review articles, non-random-
ized controlled studies, studies that did not involve patients with
pneumonia and studies of G-CSF prophylaxis rather than ther-
apy). One additional study was identified using EMBASE (n =
81), online searches of clinical trials registers (n = eight) or CEN-
TRAL (The Cochrane Library, 2004, issue 1) (n = 11). The authors
of this review conducted one as-yet unpublished study in 2003 to
2005 (Cheng 2006). A repeat search in 2006 did not identify any
further studies, although one trial previously cited as unpublished
had since been published (Hartmann 2005)
Included studies
Five of the six remaining studies were sponsored by Amgen,
the manufacturers of filgrastim. All studies met the definitions
of community-acquired pneumonia and confirmed hospital-ac-
quired pneumonia where indicated. Patients in the later two stud-
ies (Root 2003; Wunderink 2001) included patients that met our
definition for severe sepsis.
Following the initial clinical trial, a subsequent trial (Nelson 2000)
included patients with community-acquired multilobar pneumo-
nia, as the previous trial had suggested that this group, recognized
as a group at higher risk for mortality, might have benefited from
G-CSF. In this study (n = 480), there were fewer diabetics in the
intervention group, but they were otherwise well balanced. The
primary endpoint was a composite endpoint of organ dysfunc-
tion, empyema or death. Mortality and markers of adverse events,
including organ dysfunction was reported.
A small trial (Wunderink 2001; n = 18) was conducted specifically
in patients with pneumonia and septic shock primarily to evaluate
safety. Patients were randomized 2:1 to filgrastim (300 mcg / day
for five days) or placebo and included patients with both com-
munity-acquired and hospital-acquired pneumonia. Mortality at
seven and 28 days as well as markers of adverse events including
organ dysfunction was reported.
Following the safety analysis of the previous study, a large study
(Root 2003; n = 701) evaluated filgrastim (300 mcg / day for
five days) in patients with severe sepsis and community-acquired
or hospital-acquired pneumonia requiring admission to intensive
care. Neutropenic patients and those who had received chemo-
therapy were not excluded. Intervention and control groups were
well balanced at baseline. Mortality at 28 days and total adverse
events were reported. Unpublished data regarding specific rates
of organ dysfunction was provided by the study sponsors (Foote
2003).
A fifth trial was initially identified as an abstract in German
(with data obtained from correspondence with the authors (Kober
2004)) and subsequently published (Hartmann 2005; n = 29).
This study enrolled patients with hospital-acquired pneumonia
but was terminated early due to poor enrolment. G-CSF was ad-
ministered according to a weight-based protocol (300 mcg / day
for patients less than 75 kg, 480 mcg / day for patients more than
75 kg; for up to seven days). Mortality at 15 days was the primary
endpoint but 30-day mortality was also reported. Rates of serious
adverse events were sought, as were rates of ARDS.
A small sixth trial was conducted in Thailand in patients with se-
vere sepsis due to suspectedmelioidosis (a tropical infection due to
Burkholderia pseudomallei (B. pseudomallei)) (Cheng 2006). Study
subjects were allocated to receive lenograstim (263 mcg intra-
venously daily for three days). Although treatment allocation was
by computer generated list and pre-prepared boxes, only treating
clinicians and investigators were blinded to the treatment. Of the
60 patients enrolled, 36 had pneumonia and this datawas included
in this review; G-CSF was not associated with a mortality benefit
in all patients, those with melioidosis or those with pneumonia.
The primary outcome measure was 28-day mortality. Due to the
short survival of patients in this study, adverse events were not able
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to be attributed to treatment.
The bacterial aetiology was similar in all studies, with Strepto-
coccus pneumoniae (S. pneumoniae) the most common organism
found. In the studies of patients with septic shock, there was a
greater proportion of Staphylococcus aureus (S. aureus) compared to
Haemophilus influenzae (H. influenzae) reflecting the more severe
illness that accompanies infection with S. aureus. Gram negative
organisms predominated in the study of patients with hospital-
acquired pneumonia (Hartmann 2005) and the Thai study which
enrolled patients with suspected melioidosis (due to B. pseudoma-
llei) (Cheng 2006).
Excluded studies
Ten studies were identified for detailed evaluation. Correspon-
dence with the study sponsors confirms that a then-unpublished
study of G-CSF in pneumococcal pneumonia referred to in Nel-
son (Nelson 2000) refers to a subgroup of Root (Root 2003). Of
the remaining studies, one was not a randomized controlled trial
(Hustinx 1998).One study (Meyanci 2001) did not report clinical
endpoints such as mortality and the rate of organ dysfunction and
thus was excluded from further analysis. Another study reported
primarily immunological endpoints following a single dose of fil-
grastim (Droemann 2006). A small pilot study was excluded as
study subjects were administered a range of doses of G-CSF but
no placebo group was included (deBoisblanc 1997).
An initial clinical trial (Nelson 1998) excluded patients with sep-
tic shock, regarded as high risk for developing ARDS, and was
conducted in multiple sites in North America and Australia. It
included only patients with community-acquired pneumonia re-
quiring hospital admission. Although patients were required to
have two risk factors that had been demonstrated to be associated
with increased mortality, patients with septic shock were specifi-
cally excluded. In this large study (n = 756), filgrastim (300 mcg
/ day for 10 days) and control groups were balanced with regard
to risk factors. The primary end point was a composite measure
of clinical findings (“time to resolution of morbidity”), but other
endpoints were reported.
Risk of bias in included studies
There was general agreement between the study review authors; a
number ofminor issues regarding outcomemeasures were resolved
by discussion.
Follow up was generally good but incomplete in between 3% to
7.9% of participants.
Allocation
The method of randomization and generation of allocation se-
quence was only reported in one paper (Root 2003), but contact
with the study authors and sponsors confirms that computer-gen-
erated randomization lists and a priori numbered boxes were used
in each centre in all studies (Foote 2003).
Blinding
It is likely that blinding after allocation of healthcare providers and
observers may have been incomplete as median white cell counts
were much higher in the G-CSF treated groups (Nelson 1998;
Nelson 2000) but the degree of blinding was not formally assessed.
Effects of interventions
Six studies with a total of 2018 patients were identified.
Mortality and other efficacy endpoints
None of the studies demonstrated a statistically significant mortal-
ity benefit; a pooled estimate of efficacy similarly did not demon-
strate a significant benefit associated with G-CSF. There was some
heterogeneity amongst studies with regard to 28-day mortality (P
= 0.13, I-squared (I2) = 41%) but this was not statistically signif-
icant. Pooling results across all five studies, the pooled odds ratio
for 28-day mortality was 0.81 (random-effects model), 95% con-
fidence interval (CI) 0.52 to 1.27).
A number of the endpoints intended for analysis were not re-
ported, including time tohospital discharge (no interquartile range
reported in any study), the rate of intubation (only reported in
Nelson1998), in-hospitalmortality (only reported inNelson 1998
and Hartmann 2005). Duration of ICU stay was not reported
in one study (Wunderink 2001); in the remaining four studies,
no differences were seen in median ICU stay which ranged from
four days in both groups (Nelson 1998) to 16 days in both groups
(Hartmann 2005), reflecting the severity of illness of each study
population
Adverse events
Overall, there was a reduction in adverse events that was not sta-
tistically significant (pooled odds ratio was 0.79; 95% CI 0.50 to
1.23). This was largely due to a reduction in rates in organ dys-
function, highest in the study of community-acquired pneumonia
(Nelson 1998). In that study, there was a significant decrease in
rates of ARDS (OR 0.28; 95% CI 0.09 to 0.28) but this was not
seen in subsequent studies; overall use of G-CSF was not associ-
ated with a reduction in ARDS (OR 0.92; 95% CI 0.44 to 1.93).
When considering rates of individual organ dysfunction, there was
a moderate decrease in the rates of disseminated intravascular co-
agulation (OR0.74; 95%CI 0.38 to 1.44), acute renal failure (OR
0.79; 95% CI 0.48 to 1.31) and incident septic shock (OR 0.61;
95% CI 0.34 to 1.09), but this was not statistically significant.
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community-acquired pneumonia, hospital-acquired
pneumonia and ventilator-associated pneumonia
Only two of the three studies that included patients with hospital-
acquired pneumonia reported results by category. In the larger
study (Root 2003), patients with hospital-acquired pneumonia
constituted a minority (20%) of patients and were distributed
evenly in intervention and placebo groups.
Presence of severe sepsis
Outcome measures were not reported by the presence or absence
of severe sepsis in the earlier trials. (Nelson 1998; Nelson 2000).
In these trials, however, septic shock was a specific exclusion; the
pooled odds ratio of incident septic shock was 0.60 (95% CI 0.34
to 1.08). There was a moderate decrease in 28-day mortality in
these trials (pooled OR 0.80; 95% CI 0.52 to 1.22) that was not
statistically significant.
There was a trend to an increasing odds ratio of serious adverse
events and organ dysfunction in the studies of patients with severe
sepsis in filgrastim-treated patients (Root 2003;Wunderink 2001).
For total serious adverse events, the pooled odds ratio (random-
effects) in the studies of patients with severe sepsis was 1.10 (95%
CI 0.82 to 1.49) compared to the other studies (0.72; 95% CI
0.51 to 1.01). Mortality was higher in the G-CSF groups in the
largest trial that included severe sepsis (Root 2003, OR 1.2, 95%
CI: 0.86 to 1.67, which did not exclude patients with neutropenia)
but lower in the two small trials (OR 0.17, 0.12 respectively, not
pooled due to clinical heterogeneity) (Cheng 2006; Hartmann
2005).
Bacterial aetiology
Results were not reported by bacterial etiology; it was not possible
to draw conclusions on the efficacy of G-CSF in each of these
groups.
Analyses of patients with specific co-morbidities
We were also unable to perform subgroup analyses on patients
with specific co-morbid conditions due to a lack of data.
Sensitivity analysis
Given the small number of studies, we did not perform a sensitivity
analysis.
Assessment of publication bias
No individual study demonstrated a mortality benefit. The ability
to interpret a funnel plot was limited by the small number of trials
identified.
D I S C U S S I O N
Efficacy
This analysis suggests that G-CSF may be associated with a small
mortality benefit, but there is considerable uncertaintywith a plau-
sible range of outcomes ranging from a 48% reduction in mortal-
ity odds to a 27% increase in mortality odds. Richard Root (Root
2003) suggests several reasons for the failure of previous animal
work to demonstrate a clear benefit in humans; invalid hypothe-
sis, inadequate dosing or activity, improper study design or failed
execution. He suggests that, primarily, delays in the administra-
tion of G-CSF to satisfy microbiological study criteria may have
contributed to its negative result.
Adverse events
Our results suggest that G-CSF does not increase the rates of im-
munologically mediated organ dysfunction by a clinically signifi-
cant extent. A theoretical concern has been that the use of G-CSF
may increase the rate of immunologicallymediated end-organ dys-
function, such as acute respiratory distress syndrome (ARDS), to
which patients with severe sepsis are particularly prone.
There was a trend towards an increasing risk of organ dysfunction
in patients more severely unwell and treated with G-CSF, suggest-
ing that this may have been due to an exacerbation of immuno-
logically mediated disease in patients more at risk of developing
organ dysfunction. However, this was not statistically significant
in any study and remains speculative. The trend towards a reduc-
tion in incident septic shock in patients without this complication
at study enrolment may suggest that G-CSF may be operating to
prevent this complication.
Decision to pool data from trials
Despite the clinical heterogeneity present between the study pop-
ulations, we felt it appropriate to pool the results to obtain an
overall estimate of efficacy. It was felt that although the inclusion
criteria were different, these patients all had varying severity of the
same disease and thus the relative efficacy might be expected to
remain the same in each group, although the absolute benefit (or
harm) might be expected to vary with the mortality of the popu-
lation studied. Differences in management, and more particularly
antibiotics used, may have contributed to heterogeneity, but an
analysis by antibiotic group was not possible. Similarly, it was felt
that, although patients with severe sepsis may be a higher risk of
developing this complication, the mechanism of end-organ dys-
function was the same.
7Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Possible sources of bias
We felt that given the lack of effect demonstrated by the individ-
ual published trials, a significant publication bias is unlikely to be
operating. However, it is possible that trials may have been with-
held from publication due to harmful effects. We have no specific
information suggesting this possibility.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence supporting the routine use of G-
CSF in the treatment of pneumonia. There is no data on the use
of G-CSF in subgroups such as diabetics that may manifest func-
tional neutrophil deficits.We have not identified anymethodolog-
ical issues or biases that may have influenced our pooled results.
Implications for research
Clinical trials where G-CSF was administered earlier in the course
of disease or perhaps even prophylactically to prevent hospital-
acquired infection in high risk patients might be of interest. Sim-
ilarly, studies of G-CSF for organisms where neutrophil function
may be more important, or in hosts with co-morbid illnesses that
may manifest acquired neutrophil dysfunction may be of interest.
Researchers are encouraged to report methodological parameters,
such as generation of allocation sequence, allocation concealment,
blinding and loss to follow up as well as standardized outcome
measures. A useful parameter that may have an impact on out-
come, the proportion of patients on appropriate antibiotics within
the first 24 hours of therapy, should also be reported.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cheng 2006
Methods Single center, single blinded RCT
Participants Community-acquired severe sepsis
Interventions Lenograstim 263 mcg iv 3 days
Outcomes 30 day mortality, duration of survival
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hartmann 2005
Methods Single center, double blinded RCT
Participants Hospital-acquired pneumonia in ICU patients
Interventions G-CSF 300 mcg/day or 480 mcg/day for up to 7 days versus placebo
Outcomes 15 day mortality, safety, duration of antibiotic therapy
Notes Study terminated early due to poor enrolment
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Nelson 1998
Methods Multicenter, double blinded RCT
Participants Community-acquired pneumonia in hospitalized adults.
Interventions G-CSF 300 mcg/day for 10 days versus placebo
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Nelson 1998 (Continued)
Outcomes Time to resolution of morbidity, 28-day mortality, time to ICU and hospital discharge, adverse events
including organ dysfunction
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Nelson 2000
Methods Multicenter, double blinded RCT
Participants Community-acquired multilobar pneumonia in hospitalized adults
Interventions G-CSF 300 mcg/day for 10 days versus placebo
Outcomes 28-day mortality, therapeutic failure, adverse events including organ dysfunction
No difference in organ dysfunction
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Root 2003
Methods Multicenter, double blinded RCT
Participants Confirmed hospital-acquired or community-acquired pneumonia with severe sepsis
Interventions G-CSF 300 mcg/day for 5 days versus placebo
Outcomes 28 day mortality, time to ICU discharge, adverse events
Notes
Risk of bias
Item Authors’ judgement Description
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Root 2003 (Continued)
Allocation concealment? Yes A - Adequate
Wunderink 2001
Methods Double blinded RCT in 3 centres in the US
Participants Confirmed hospital-acquired or community-acquired pneumonia with severe sepsis
Interventions G-CSF 300 mcg/d for 5 days versus placebo
Outcomes Safety
Notes Small study. Heterogenous population
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
mcg = micrograms
iv = intravenously
ICU = intensive care unit
RCT = randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
deBoisblanc 1997 Dose ranging pilot study; no control group included
Droemann 2006 Controlled trial of single dose of G-CSF, but with immunological endpoints: few clinical endpoints reported
Hustinx 1998 Not a randomized controlled trial
Meyanci 2001 Clinical endpoints, such as mortality or rates of organ dysfunction, were not reported
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 28 day mortality 6 2018 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.52, 1.27]
Comparison 2. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any adverse event (including
organ dysfunction)
5 1984 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.50, 1.23]
2 Adult respiratory distress
syndrome
5 1984 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.44, 1.93]
3 Disseminated intravascular
coagulation
4 1953 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.38, 1.44]
4 Acute renal failure 4 1953 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.48, 1.31]
5 Septic shock 2 1236 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.34, 1.09]
WH A T ’ S N E W
Last assessed as up-to-date: 28 January 2007.
Date Event Description
6 August 2009 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 4, 2003
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Date Event Description
8 May 2009 Amended Contact details updated.
21 August 2008 Amended Converted to new review format.
9 March 2004 New search has been performed Searches conducted.
24 April 2003 New search has been performed Searches conducted.
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